Newsfeeds - Spark Newswire

1 minute read

Earnings

Return on Capital Employed Insights for ChromaDex

Today, 10:48 PM

After pulling data from Benzinga Pro it seems like during Q2, ChromaDex's (NASDAQ:CDXC) reported sales totaled $17.70 million. Despite a 24.56% in earnings, the company posted a loss of $5.55 million.

CDXC

1 minute read

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $12

By Benzinga Newsdesk

Today, 10:48 PM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $11 to $12.

CDXC

1 minute read

ChromaDex Q2 EPS $(0.08), Inline, Sales $17.70M Beat $17.16M Estimate

By Benzinga Newsdesk

Today, 10:48 PM

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent decrease over losses of $(0.06) per share from the same period last year. The

CDXC

21 minute read

Earnings Scheduled For August 3, 2021

By Benzinga Insights

Today, 10:48 PM

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

AAIC

1 minute read

Watching ChromaDex Shares As Traders Circulate Study ‘Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19’

By Bill Haddad

Today, 10:48 PM

https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222<

CDXC

1 minute read

ChromaDex Shares See Volume; J Capital Issues Negative Note On Co Titled ‘Unhealthy A Full Dose of Promotion’

By Benzinga Newsdesk

Today, 10:48 PM

https://www.jcapitalresearch.com/cdxc-terms-of-service.html

CDXC

3 minute read

ChromaDex Highlights Research Findings From ChromaDex External Research Program

By Bill Haddad

Today, 10:48 PM

New preclinical research in mice finds nicotinamide riboside (NR) prevented loss of bone mass, reduced neuroinflammation, and reduced the negative effects of alcohol-induced inflammation ChromaDex Corp. (NASDAQ:CDXC)

CDXC

2 minute read

EXCLUSIVE: Chromadex CEO To Ring Nasdaq Closing Bell, Talks Walmart Product Launch

By Wayne Duggan

Today, 10:48 PM

Chromadex Corp (NASDAQ: CDXC) is participating in the Nasdaq’s closing bell ceremony on Thursday afternoon to celebrate its five-year anniversary of trading on the exchange.

CDXC